Definium Therapeutics, Inc. (DFTX)
DFTX Stock Price Chart
Explore Definium Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze DFTX price movements and trends.
DFTX Company Profile
Discover essential business fundamentals and corporate details for Definium Therapeutics, Inc. (DFTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
15 Nov 2016
Employees
74.00
Website
https://definiumtx.comCEO
Robert Barrow
Description
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
DFTX Financial Timeline
Browse a chronological timeline of Definium Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is -$0.55.
Earnings released on 7 May 2026
EPS came in at -$0.71 falling short of the estimated -$0.47 by -51.06%.
Earnings released on 26 Feb 2026
EPS came in at -$0.51 falling short of the estimated -$0.48 by -5.44%.
Earnings released on 6 Nov 2025
EPS came in at -$0.78 falling short of the estimated -$0.52 by -50.00%.
Earnings released on 31 Jul 2025
EPS came in at -$0.50 falling short of the estimated -$0.38 by -31.58%.
Earnings released on 8 May 2025
EPS came in at -$0.35 surpassing the estimated -$0.36 by +2.78%.
Earnings released on 6 Mar 2025
EPS came in at -$0.41 falling short of the estimated -$0.33 by -24.24%.
Earnings released on 7 Nov 2024
EPS came in at -$0.27 surpassing the estimated -$0.29 by +6.90%.
Earnings released on 13 Aug 2024
EPS came in at -$0.48 falling short of the estimated -$0.30 by -60.00%.
Earnings released on 8 May 2024
EPS came in at -$0.60 surpassing the estimated -$0.66 by +9.09%.
Earnings released on 28 Feb 2024
EPS came in at -$0.59 falling short of the estimated -$0.48 by -22.92%, while revenue for the quarter reached $4.84m .
Earnings released on 2 Nov 2023
EPS came in at -$0.53 surpassing the estimated -$0.65 by +18.46%.
Earnings released on 3 Aug 2023
EPS came in at -$0.72 falling short of the estimated -$0.54 by -33.33%.
Earnings released on 4 May 2023
EPS came in at -$0.51 falling short of the estimated -$0.41 by -24.39%.
Earnings released on 9 Mar 2023
EPS came in at -$0.27 surpassing the estimated -$0.49 by +44.90%.
Earnings released on 10 Nov 2022
EPS came in at -$0.56 surpassing the estimated -$0.58 by +3.45%.
Stock split effective on 29 Aug 2022
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 Aug 2022
EPS came in at -$0.60 surpassing the estimated -$0.75 by +20.00%.
Earnings released on 16 May 2022
EPS came in at -$0.60 surpassing the estimated -$0.75 by +20.00%.
Earnings released on 28 Mar 2022
EPS came in at -$0.75 falling short of the estimated -$0.70 by -7.14%.
Earnings released on 12 Nov 2021
EPS came in at -$0.90 falling short of the estimated -$0.52 by -73.08%.
Earnings released on 12 Aug 2021
EPS came in at -$1.35 falling short of the estimated -$0.60 by -125.00%.
DFTX Stock Performance
Access detailed DFTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
